首页|奥美沙坦酯片在中国健康受试者中的生物等效性研究

奥美沙坦酯片在中国健康受试者中的生物等效性研究

扫码查看
目的 评价奥美沙坦酯片受试制剂与参比制剂在中国健康受试者中单剂量空腹和餐后条件下给药的生物等效性.方法 用单中心、随机、开放、单次给药、两制剂、两周期交叉试验设计,空腹和餐后试验各入组24例受试者.空腹或餐后条件下单次口服奥美沙坦酯片受试制剂和参比制剂20 mg.用液相色谱串联质谱法测定血浆中奥美沙坦的浓度,用Phoenix WinNonlin 8.0软件计算主要药代动力学参数.结果 空腹试验奥美沙坦酯片受试制剂和参比制剂主要药代动力学参数:Cmax 分别为(653.06±133.53)和(617.37±151.16)ng·mL-1,AUC0-t分别为(4 201.18±1 035.21)和(4 087.38±889.99)ng·mL-1·h,AUC0-∞ 分别为(4 254.30±1 058.90)和(4 135.69±905.29)ng·mL-1·h.餐后试验奥美沙坦酯片受试制剂和参比制剂主要药代动力学参数:Cmax分别为(574.78±177.05)和(579.98±107.74)ng·mL-1,AUC0-t 分别 为(3 288.37±866.06)和(3 181.51±801.06)ng·mL-1·h,AUC0-∞ 分别为(3 326.11±874.26)和(3 242.01±823.09)ng·mL-1·h.在空腹和餐后条件下,受试制剂与参比制剂主要药代动力学参数的90%置信区间均在80.00%~125.00%.结论 空腹和餐后条件下,中国健康成年受试者单次口服奥美沙坦酯片受试制剂和参比制剂具有生物等效性.
Bioequivalence study of olmesartan medoxomil tablet in Chinese healthy subjects
Objective To study the bioequivalence of test and reference olmesartan tablet in Chinese healthy subjects after single dose under fasting and fed conditions.Methods A single-center,random,open,single-dose,two-preparations,double-period,crossover study was adopted.A total of 48 healthy adult male and female subjects(24 cases of fasting test and 24 cases of fed test)were included in the random crossover administration.Single oral dose 20 mg of test and reference were taken under fasting and postprandial conditions,respectively.Plasma concentration of olmesartan in plasma were determined by liquid chromatography tandem mass spectrometry.The main pharmacokinetic parameters were calculated by Phoenix WinNonlin 8.0 software.Results The main pharmacokinetic parameters of the test and reference preparations of olmesartan tablets in the fasting group were as follows:Cmax were(653.06±133.53)and(617.37±151.16)ng·mL-1,AUC0-t were(4 201.18±1 035.21)and(4 087.38±889.99)ng·mL-1·h,AUC0-∞ were(4 254.30±1 058.90)and(4 135.69±905.29)ng·mL-1·h.The main pharmacokinetic parameters of the test and reference preparations of olmesartan tablets in the postprandial group were as follows:Cmax were(574.78±177.05)and(579.98±107.74)ng·mL-1,AUC0-t were(3 288.37±866.06)and(3 181.51±801.06)ng·mL-1·h,AUC0-∞ were(3 326.11±874.26)and(3 242.01±823.09)ng·mL-1·h.Under fasting and postprandial conditions,the 90%confidence intervals of the main pharmacokinetic parameters of the test and reference preparations are both 80.00%-125.00%.Conclusion Under fasting and postprandial conditions,a single oral dose of test and reference preparations olmesartan tablets in Chinese healthy adult volunteers showed bioequivalence.

olmesartan medoxomil tabletbioequivalencepharmacokinetic

单娜、江大海、苗琳琳、任振丽、靳鹏博、郝沛琪、安莉、朱红、辛勇、杨广德、刘峰

展开 >

陕西国际商贸学院医药学院,陕西咸阳 712046

山东步长制药股份有限公司,山东菏泽 712000

徐州医科大学附属医院Ⅰ期临床试验研究室,江苏徐州 221000

奥美沙坦酯片 生物等效性 药代动力学

2024

中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCD北大核心
影响因子:1.91
ISSN:1001-6821
年,卷(期):2024.40(20)